Issue Date: July 4, 2011
Pfizer Considers Deal With Icagen
Pfizer is evaluating the possibility of extending or amending its collaborative relationship with Icagen or increasing its ownership stake in the smaller firm. R&D partners since 2007, the two companies have already twice extended their agreement, which expires in December. In the past four years, Pfizer has spent $15 million to buy about 1.1 million shares of Icagen stock, or about 15% of the company’s outstanding shares. Icagen confirms that it is conducting preliminary discussions with Pfizer regarding a potential transaction.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society